Showing 2531-2540 of 3039 results for "".
- Retrotope Reports Positive Results from Studies of RT011 in Animal Models of Retinal Degenerationhttps://modernod.com/news/retrotope-reports-positive-results-from-studies-of-rt011-in-animal-models-of-retinal-degeneration/2480361/Retrotope announced that positive results from preclinical studies of RT011, the second compound to emerge from the company’s novel technology platform, are being reported
- Ocuphire’s Clinical Phase 2b Oral Drug Candidate APX3330 for Diabetic Retinal Disease to be Featured at the OIS Retina@ASRS and ASRS 2021 Annual Meetinghttps://modernod.com/news/ocuphires-clinical-phase-2b-oral-drug-candidate-apx3330-for-diabetic-retinal-disease-to-be-featured-at-the-ois-retina-at-asrs-and-asrs-2021-annual-meeting/2480315/Ocuphire Pharma announced that its clinical-stage, novel oral Ref-1 inhibitor, APX3330, for the treatment of diabetic retinal disease will be featured at the Ophthalmology Innovation Summit (OIS) Retina@ASRS Innovation Company Showcase on October 7 in San Antonio, TX. The APX333
- Visus Unveils Additional Ophthalmic Drug Candidates for Corneal Wound Healing, Glaucoma and AMDhttps://modernod.com/news/visus-unveils-additional-ophthalmic-drug-candidates-for-corneal-wound-healing-glaucoma-and-amd/2480276/During its inaugural Capital Markets Day in New York City, Visus Therapeutics unveiled additional ophthalmic drug candidates with applications in development for corneal wound healing, glaucoma and age-related macular degeneration (AMD). Additionally, the company introduced a novel drug
- Clearside Biomedical Expands Xipere License Agreement with Arctic Visionhttps://modernod.com/news/clearside-biomedical-expands-xipere-license-agreement-with-arctic-vision/2479500/Clearside Biomedical announced it has agreed to expand the territories covered by its exclusive license agreement with China-based Arctic Vision. As now amended, the licensed territory for Xipere (triamcinolone acetonide suprachoroidal injectable suspension) has been expanded from
- Oxurion to Present Clinical and Preclinical Data at Upcoming Euretina 2021 Virtual Congresshttps://modernod.com/news/oxurion-to-present-clinical-and-preclinical-data-at-upcoming-euretina-2021-virtual-congress/2479493/Oxurion NV will be presenting preclinical and clinical data from its ongoing development programs, THR-149 and THR-687, as novel treatments for diabetic macular edema (DME) at the Euretina 2021 virtual congress. The upcoming annual meeting of the European Society of Retina Specialists is taking p
- AxeroVision Announces Phase 2 Results for Dry Eye Disease Creamhttps://modernod.com/news/axerovision-announces-phase-2-results-for-axr-270-for-treatment-of-dry-eye-disease-associated-with-mgd/2479478/AxeroVision announced positive results from a phase 2 investigational treatment of AXR-270, the company’s novel, proprietary, once-daily glucocorticoid cream, in patients with signs and symptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD). I
- Complexity Gaming Kicks Off Year-Long Partnership With Alconhttps://modernod.com/news/complexity-gaming-kicks-off-year-long-partnership-with-alcon/2479475/Esports company Complexity Gaming announced a partnership with Alcon. The partnership will designate Alcon’s signature brand of lubricant eye drops, Systane, as the first official eye care partner of Complexity Gaming. Now more than ever, dry eye symptoms are affecting people due to increa
- Pfizer, BioNTech’s COVID-19 Vaccine Bags Full FDA Approvalhttps://modernod.com/news/pfizer-biontechs-covid-19-vaccine-bags-full-fda-approval/2479467/The FDA on Monday approved Pfizer and BioNTech’s BNT162b2, now known in the US as Comirnaty, to prevent COVID-19 in people ages 16 years and older, making it the first coronavirus vaccine to have its emergency-use authorization (EUA) converted into a full approval. “While millions of
- Oxurion Announces Publication of Positive Phase 1 Clinical Data Evaluating THR-687 for Treatment of DMEhttps://modernod.com/news/oxurion-announces-publication-of-positive-phase-1-clinical-data-evaluating-thr-687-for-treatment-of-dme/2479451/Oxurion announced that the positive phase 1 study of THR-687, a novel, highly potent integrin agonist for the treatment of DME has just been published in Ophthalmology Science. The multicenter, dose escalation study was designed to evaluate the safety and preliminary efficacy of t
- CooperVision MiSight 1-Day Contact Lens Approved in Chinahttps://modernod.com/news/coopervision-misight-1-day-contact-lens-approved-in-china/2479445/The Chinese National Medical Products Administration (NMPA) has approved CooperVision MiSight 1 day contact lenses for use within the country following a priority review. The innovative soft contact lenses have now become the first indicated product of any type in China that may slow the progress